Anne Carpenter, one of In Vivo’s 2021 Rising Leaders, talks about the growth of open source technology, putting data into action and why pharma deserves to be rewarded for evolving academic findings into marketable products for patients.
Back To Rising Leaders Gallery
When Anne Carpenter started her lab at the Broad Institute of MIT and Harvard, it was not trendy to be open and free with your work
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.
While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.
Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.
In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.
